Hospital

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.

Early detection of chronic kidney disease is vital to preventing comorbid conditions.

The phase 2 study will evaluate the efficacy and safety of 2 different doses of MK-2060 in patients with ESRD receiving hemodialysis via an arteriovenous graft.

The 4 academic centers will evaluate the role of telehealth in areas such as prevention, screening, diagnosis, treatment, and survivorship.

Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.

Survey data indicates that people experiencing homelessness had a lower annual incidence of COVID-19 despite having a higher burden of infectious diseases, suggesting opportunities for better integration of homelessness status in infectious disease reporting.

Results also show that no association with an increased frequency of myocarditis, venous thromboembolism, or worsening HF in these individuals.

The mRNA-1273.222 vaccine candidate targets both the original SARS-CoV-2 strain in addition to the BA.4/BA.5 subvariants of the Omicron strain.

Danish analysis looks at the relationship between the therapy and cardiovascular adverse effects, particularly arrhythmias.

Long-term follow up on the KEYNOTE-604 study suggests pembrolizumab plus etoposide/platinum is a superior first-line therapy for small cell lung cancer vs placebo.

In New York’s medical cannabis program, research showed that patients’ preference around potency differed among users, regardless of their health conditions.

The companies are prepared to deliver doses of the Omicron-adapted bivalent vaccine for September, pending authorization.

Less than half of fully vaccinated individuals in the United States have received a COVID-19 booster dose, with lower uptake rates among individuals with less education, lower socioeconomic status, and current enrollment in Medicaid.

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses the stigma around drug diversion and the best ways to address and fight that stigma.

A P79S ORF2 variant demonstrates reduced RNA copy numbers released in the supernatant and impaired the production of infectious disease particles, investigators said.

Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.

Overall low awareness of the Omicron variant infection contributed to high transmission rates and rapid spread of SARS-CoV-2 in communities.

Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses his experience with drug diversion and addiction.

Narcissistic leaders have a negative impact on the culture of their organization as their conduct and management style induces fear.

The announcement marks the first protein-based COVID-19 vaccine authorized in the United States for this patient population.

The regulatory submission includes data from the MOMENTUM phase 3 clinical trial that met all primary and key second efficacy end points.

University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.

The American Heart Association includes 6 conditions and indicates that men’s and women’s experiences may differ.

Zerbaxa is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor.

Treatment with empagliflozin also found to improve cardiac geometry, myocardial mechano-energetic efficiency, and cardiac function.

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.